Members of the hypoxia-inducible factor (HIF) family of transcription factors regulate the cellular response to
hypoxia (1). HIF2-Alpha is involved in catecholamine
homeostasis, vascular remodeling, physiological
angiogenesis and adipogenesis. It is overexpressed in
many cancerous tissues, but its exact role in tumour
progression remains to be clarified (2). Studies suggest
that in the case of non-small cell lung cancer, HIF2-Alpha
actually is a promoter of tumor growth and progression in
a solid tumor (1). Other data suggests that HIF2-Alpha is
an important regulator of innate immunity, and therefore
may be useful in the therapeutic target for treating
inflammatory disorders and cancer (3).